How Entresto Reduces Heart Failure Symptoms
Entresto (sacubitril/valsartan) treats chronic heart failure with reduced ejection fraction (HFrEF) by combining two actions in one pill: sacubitril inhibits neprilysin, an enzyme that breaks down protective hormones, while valsartan blocks angiotensin II receptors. This dual mechanism boosts natriuretic peptides like BNP and ANP, which relax blood vessels, reduce blood pressure, and promote sodium excretion to ease fluid buildup. It also lowers aldosterone and angiotensin II effects, cutting sodium retention and fibrosis in the heart.[1][2]
Patients often notice less shortness of breath, fatigue, and swelling within weeks, with studies showing it cuts hospitalization risk by 20% and cardiovascular death by 16% compared to ACE inhibitors like enalapril.[3]
What Happens in the Body Step by Step
- Neprilysin inhibition raises levels of natriuretic peptides, countering the harmful renin-angiotensin-aldosterone system (RAAS).
- Valsartan directly blocks RAAS, preventing vessel constriction and heart strain.
- Combined, this unloads the heart, improves ejection fraction over time, and slows remodeling that worsens failure.[1][4]
Unlike traditional ACE inhibitors, Entresto avoids bradykinin buildup, reducing cough risk.
Who Qualifies and When Doctors Prescribe It
Guidelines from the American College of Cardiology recommend Entresto for HFrEF patients (NYHA class II-IV) with ejection fraction below 40%, especially after ACE/ARB failure or intolerance. It's not for preserved ejection fraction (HFpEF) or acute decompensated failure.[2][5]
Switching from ACE inhibitors requires a 36-hour washout to avoid angioedema.
Common Side Effects Patients Report
Hypotension (14%), hyperkalemia (10%), and kidney function changes top the list. Cough is rarer (2%) than with ACE inhibitors. Monitor blood pressure and potassium closely at start.[1][3]
How It Stacks Up Against ACE Inhibitors and ARBs
| Drug Class | Key Difference | Hospitalization Reduction |
|------------|----------------|---------------------------|
| Entresto | Neprilysin + ARB | 20-21% vs. enalapril [3] |
| ACEi (e.g., enalapril) | RAAS block only | Baseline |
| ARB (e.g., valsartan) | Similar to ACEi, no cough | 13% less effective [6] |
PARADIGM-HF trial proved superiority, leading to FDA approval in 2015.[3]
Long-Term Outlook and Survival Data
In trials, Entresto extended life by months on average; 5-year data show sustained benefits. Real-world use confirms lower readmissions.[4][7]
Patent on sacubitril/valsartan expires in 2025 in the US—check DrugPatentWatch.com for generics timeline.[8]
Sources
[1]: Entresto Prescribing Information, Novartis, 2023. https://www.novartis.com/us-en/sites/novartisus/files/entresto.pdf
[2]: FDA Label. https://www.accessdata.fda.gov/drugsatfdadocs/label/2015/207620s000lbl.pdf
[3]: NEJM, PARADIGM-HF Trial, 2014. https://www.nejm.org/doi/full/10.1056/NEJMoa1409077
[4]: Circulation, Mechanism Review, 2018. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.034397
[5]: ACC/AHA Heart Failure Guidelines, 2022. https://www.jacc.org/doi/10.1016/j.jacc.2021.12.012
[6]: VAL-HeFT Trial, NEJM 2001. https://www.nejm.org/doi/full/10.1056/NEJMoa010976
[7]: Lancet, Long-term PARADIGM-HF, 2019. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31894-9/fulltext
[8]: DrugPatentWatch.com. https://www.drugpatentwatch.com/p/tradename/ENTRESTO